Literature DB >> 20359747

The role of Bcl-2 family proteins in chronic lymphocytic leukaemia.

Andrea G S Buggins1, Chris J Pepper.   

Abstract

Bcl-2 family proteins have long been implicated in the pathology of chronic lymphocytic leukaemia (CLL). Indeed, a number of these proteins have been shown to have prognostic importance in this disease. The precise ways in which these proteins impact upon CLL and the ways in which they are regulated remain incompletely resolved. However, significant advances have been recently made in our understanding of how these proteins are controlled by genetic, epigenetic and microenvironmental cues. Furthermore, major progress has been made in trying to target these proteins therapeutically. Here we review the current knowledge about this family of apoptosis-regulating proteins and how they impact upon drug resistance and disease progression. We also summarise evolution in the development of Bcl-2 family inhibitors for the treatment of CLL and other cancers. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20359747     DOI: 10.1016/j.leukres.2010.03.011

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  28 in total

Review 1.  Know the enemy as well as the weapons in hand: the aberrant death pathways and therapeutic agents in chronic lymphocytic leukemia.

Authors:  Ying Huang; Jia-Zhu Wu; Jian-Yong Li; Wei Xu
Journal:  Am J Cancer Res       Date:  2015-07-15       Impact factor: 6.166

2.  Differential cytopathology and kinetics of measles oncolysis in two primary B-cell malignancies provides mechanistic insights.

Authors:  Bella Patel; Aditi Dey; Ehsan Ghorani; Shaji Kumar; Yogeshkumar Malam; Lena Rai; Andrew J Steele; Jennifer Thomson; R Gitendra Wickremasinghe; Yu Zhang; Anna Z Castleton; Adele K Fielding
Journal:  Mol Ther       Date:  2011-03-22       Impact factor: 11.454

3.  Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199).

Authors:  V M Patel; K Balakrishnan; M Douglas; T Tibbitts; E Y Xu; J L Kutok; M Ayers; A Sarkar; R Guerrieri; W G Wierda; S O'Brien; N Jain; H M Stern; V Gandhi
Journal:  Leukemia       Date:  2016-12-26       Impact factor: 11.528

Review 4.  Molecular basis of chronic lymphocytic leukemia diagnosis and prognosis.

Authors:  Mohammad Shahjahani; Javad Mohammadiasl; Fatemeh Noroozi; Mohammad Seghatoleslami; Saeid Shahrabi; Fakhredin Saba; Najmaldin Saki
Journal:  Cell Oncol (Dordr)       Date:  2015-01-07       Impact factor: 6.730

Review 5.  Apoptotic cell signaling in cancer progression and therapy.

Authors:  Jessica Plati; Octavian Bucur; Roya Khosravi-Far
Journal:  Integr Biol (Camb)       Date:  2011-02-22       Impact factor: 2.192

6.  Two novel aspirin analogues show selective cytotoxicity in primary chronic lymphocytic leukaemia cells that is associated with dual inhibition of Rel A and COX-2.

Authors:  C Pepper; J G Mahdi; A G S Buggins; S Hewamana; E Walsby; E Mahdi; A Al-Haza'a; A J Mahdi; T T Lin; L Pearce; L Morgan; I D Bowen; P Brennan; C Fegan
Journal:  Cell Prolif       Date:  2011-06-06       Impact factor: 6.831

7.  Germline variation in apoptosis pathway genes and risk of non-Hodgkin's lymphoma.

Authors:  Jennifer L Kelly; Anne J Novak; Zachary S Fredericksen; Mark Liebow; Stephen M Ansell; Ahmet Dogan; Alice H Wang; Thomas E Witzig; Timothy G Call; Neil E Kay; Thomas M Habermann; Susan L Slager; James R Cerhan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-09-20       Impact factor: 4.254

8.  SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target.

Authors:  Dale J Christensen; Youwei Chen; Jessica Oddo; Karen M Matta; Jessica Neil; Evan D Davis; Alicia D Volkheimer; Mark C Lanasa; Daphne R Friedman; Barbara K Goodman; Jon P Gockerman; Louis F Diehl; Carlos M de Castro; Joseph O Moore; Michael P Vitek; J Brice Weinberg
Journal:  Blood       Date:  2011-08-15       Impact factor: 22.113

9.  Liposome-coated lipoplex-based carrier for antisense oligonucleotides.

Authors:  Paulina Wyrozumska; Justyna Meissner; Monika Toporkiewicz; Marta Szarawarska; Kazimierz Kuliczkowski; Maciej Ugorski; Marta A Walasek; Aleksander F Sikorski
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

10.  BCL-2 inhibitors sensitize therapy-resistant chronic lymphocytic leukemia cells to VSV oncolysis.

Authors:  Sara Samuel; Vladimir Beljanski; Julien Van Grevenynghe; Stephanie Richards; Fethia Ben Yebdri; Zhong He; Carmen Nichols; S Mehdi Belgnaoui; Courtney Steel; Marie-Line Goulet; April Shamy; Dawn Brown; Guillermo Abesada; Elias K Haddad; John Hiscott
Journal:  Mol Ther       Date:  2013-05-21       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.